The stock of BriaCell Therapeutics Corp (BCTX) has seen a -23.11% decrease in the past week, with a 1.36% gain in the past month, and a -58.79% decrease in the past quarter. The volatility ratio for the week is 52.45%, and the volatility levels for the past 30 days are at 21.11% for BCTX. The simple moving average for the past 20 days is -21.09% for BCTX’s stock, with a -77.45% simple moving average for the past 200 days.
Is It Worth Investing in BriaCell Therapeutics Corp (NASDAQ: BCTX) Right Now?
Additionally, the 36-month beta value for BCTX is 1.34. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BCTX is 14.64M and currently, short sellers hold a 1.74% ratio of that float. The average trading volume of BCTX on September 16, 2024 was 3.13M shares.
BCTX) stock’s latest price update
BriaCell Therapeutics Corp (NASDAQ: BCTX)’s stock price has dropped by -11.03 in relation to previous closing price of 0.63. Nevertheless, the company has seen a loss of -23.11% in its stock price over the last five trading days. globenewswire.com reported 2024-09-12 that PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts offering priced at-the-market under Nasdaq rules for 12,325,000 common shares. Each common share was sold at an offering price of $0.69 per share, for gross proceeds of approximately $8.5 million, before deducting placement agent fees and other offering expenses. All the shares in the offering were offered by the Company.
Analysts’ Opinion of BCTX
Many brokerage firms have already submitted their reports for BCTX stocks, with H.C. Wainwright repeating the rating for BCTX by listing it as a “Buy.” The predicted price for BCTX in the upcoming period, according to H.C. Wainwright is $25 based on the research report published on February 14, 2022 of the previous year 2022.
BCTX Trading at -25.49% from the 50-Day Moving Average
After a stumble in the market that brought BCTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.28% of loss for the given period.
Volatility was left at 21.11%, however, over the last 30 days, the volatility rate increased by 52.45%, as shares sank -0.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.95% lower at present.
During the last 5 trading sessions, BCTX fell by -23.11%, which changed the moving average for the period of 200-days by -88.63% in comparison to the 20-day moving average, which settled at $0.7102. In addition, BriaCell Therapeutics Corp saw -90.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCTX starting from Lustig Marc, who purchase 902,935 shares at the price of $2.21 back on May 14 ’24. After this action, Lustig Marc now owns 2,542,935 shares of BriaCell Therapeutics Corp, valued at $2,000,001 using the latest closing price.
Stock Fundamentals for BCTX
The total capital return value is set at 63.64. Equity return is now at value -202.12, with -33.38 for asset returns.
Currently, EBITDA for the company is -22.37 million with net debt to EBITDA at 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.82.
Conclusion
In conclusion, BriaCell Therapeutics Corp (BCTX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
